AC
PVLA

Annandale Capital’s Palvella Therapeutics PVLA Stock Holding History

Annandale Capital’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-775
Closed -$10K – 148
2023
Q2 		$10K Sell
775
-63
-8% -$3.82K ﹤0.01% 138
2023
Q1 		$65K Hold
838
– – 0.02% 129
2022
Q4 		$70K Buy
838
+213
+34% +$17.1K 0.02% 128
2022
Q3 		$58K Buy
+625
New +$80.6K 0.02% 128

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Annandale Capital's PVLA Position: Q3 2023 in Review

Annandale Capital sold out of Palvella Therapeutics (PVLA) in Q3 2023, closing a stake of 775 shares — an estimated $10K sold.

Annandale Capital first reported a position in PVLA in Q3 2022 and held it in 4 quarters. The position peaked at $70K in Q4 2022. 43 funds tracked by Wall St. Rank hold PVLA as of Q3 2023.

  • Annandale Capital reported no remaining Palvella Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Annandale Capital sold 775 Palvella Therapeutics shares in Q3 2023, an estimated $10K.
  • Annandale Capital first reported a position in Palvella Therapeutics in Q3 2022 and held it in 4 quarters.
  • Annandale Capital's Palvella Therapeutics position peaked at $70K in Q4 2022.
  • 43 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2023.

Based on Annandale Capital's 13F filing for Q3 2023, filed 15 Nov 2023.